Literature DB >> 11781418

Increased CSF levels of prostaglandin E(2) in variant Creutzfeldt-Jakob disease.

L Minghetti1, F Cardone, A Greco, M Puopolo, G Levi, A J E Green, R Knight, M Pocchiari.   

Abstract

The concentration of the cyclooxygenase product prostaglandin E(2) was sixfold higher in CSF samples from 18 cases of variant Creutzfeldt-Jakob disease (CJD) than in a group of eight subjects with other noninflammatory neurologic diseases, and comparable to those found in a group of six patients affected by diseases with a known inflammatory component. This finding suggests that cyclooxygenase activity may have a role in variant CJD pathogenesis, as previously reported in sporadic CJD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11781418     DOI: 10.1212/wnl.58.1.127

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  12 in total

Review 1.  Atypical antiinflammatory activation of microglia induced by apoptotic neurons: possible role of phosphatidylserine-phosphatidylserine receptor interaction.

Authors:  Roberta De Simone; Maria Antonietta Ajmone-Cat; Luisa Minghetti
Journal:  Mol Neurobiol       Date:  2004-04       Impact factor: 5.590

Review 2.  Therapeutic targets in prostaglandin E2 signaling for neurologic disease.

Authors:  P J Cimino; C Dirk Keene; Richard M Breyer; Kathleen S Montine; Thomas J Montine
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

3.  Levels of CSF prostaglandin E2, cognitive decline, and survival in Alzheimer's disease.

Authors:  M Combrinck; J Williams; M A De Berardinis; D Warden; M Puopolo; A D Smith; L Minghetti
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-06-08       Impact factor: 10.154

4.  Phospholipase A2 inhibitors protect against prion and Abeta mediated synapse degeneration.

Authors:  Clive Bate; Mourad Tayebi; Alun Williams
Journal:  Mol Neurodegener       Date:  2010-04-08       Impact factor: 14.195

5.  Genomic and post-genomic analyses of human prion diseases.

Authors:  Maurizio Pocchiari; Anna Poleggi; Serena Principe; Silvia Graziano; Franco Cardone
Journal:  Genome Med       Date:  2009-06-22       Impact factor: 11.117

Review 6.  Pathophysiological Roles of Cyclooxygenases and Prostaglandins in the Central Nervous System.

Authors:  Tatsurou Yagami; Hiromi Koma; Yasuhiro Yamamoto
Journal:  Mol Neurobiol       Date:  2015-09-02       Impact factor: 5.590

7.  Glimepiride reduces the expression of PrPc, prevents PrPSc formation and protects against prion mediated neurotoxicity in cell lines.

Authors:  Clive Bate; Mourad Tayebi; Luisa Diomede; Mario Salmona; Alun Williams
Journal:  PLoS One       Date:  2009-12-09       Impact factor: 3.240

8.  Inhibition of cytosolic Phospholipase A2 prevents prion peptide-induced neuronal damage and co-localisation with Beta III Tubulin.

Authors:  Victoria Last; Alun Williams; Dirk Werling
Journal:  BMC Neurosci       Date:  2012-08-28       Impact factor: 3.288

9.  Sequestration of free cholesterol in cell membranes by prions correlates with cytoplasmic phospholipase A2 activation.

Authors:  Clive Bate; Mourad Tayebi; Alun Williams
Journal:  BMC Biol       Date:  2008-02-12       Impact factor: 7.431

10.  Squalestatin alters the intracellular trafficking of a neurotoxic prion peptide.

Authors:  Rona Wilson; Clive Bate; Ronald Boshuizen; Alun Williams; James Brewer
Journal:  BMC Neurosci       Date:  2007-11-22       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.